Journal of Pharmaceutical Innovation

, Volume 3, Issue 3, pp 175–187

Improving Pharmaceutical Product Development and Manufacturing: Impact on Cost of Drug Development and Cost of Goods Sold of Pharmaceuticals



It is not commonly understood that one of the largest components of the overall cost of bringing a new drug to the market is the cost of product development. Cost of product development can account for as much as 30% to 35% of the total cost of bringing a new drug to the market. Quality of product development also affects time to market and the quality of manufacturing and therefore cost of manufacturing. Investment in basic research in the science of product development and manufacturing will pay for itself through savings achievable in the cost of new drug development and in the cost of goods sold (COGS) of pharmaceutical products. In order for us to arrive at good estimates of the saving potential, one first needs to have credible estimates of the cost of new drug development and the overall COGS for pharmaceutical products.


Product development Drug development cost COGS Savings potential 


  1. 1.
    Basu PK. Pharmaceutical process development is different. Chem Eng Prog 1998;94:75–82.Google Scholar
  2. 2.
    Pisano G. The development factory: unlocking the potential of process innovation. Boston: Harvard Business School Press; 1997.Google Scholar
  3. 3.
    Leila A, Henry S. New prescriptions for drug makers: update the plants. Wall Street Journal, September 12, 2003.Google Scholar
  4. 4.
    US Department of Health and Drug Administration. Challenge and opportunity on the critical path to new medical products. Rockville: US Department of Health and Drug Administration; 2004. March.Google Scholar
  5. 5.
    Cohen N. PAT: process analytical technology as FDA and industry effort. In: ISPE Midwest Chapter Meeting, 2005.Google Scholar
  6. 6.
    Hussain A. The process analytical technology initiative: PAT and pharmacopeias. In: EDQM Spring Conference, Cannes, 2004.Google Scholar
  7. 7.
    Hussain A. ACPS Meeting, 2001.Google Scholar
  8. 8.
    Woodcock J. Issues in drug quality regulation. March 12, 2002.Google Scholar
  9. 9.
    NIPTE. Strategic roadmap for pharmaceutical technology. Des Plaines: NIPTE; 2008.Google Scholar
  10. 10.
    Vernon JA, Hughen KW, Trujilli AJ. Pharmaceutical manufacturing efficiency, drug prices, and public health: examining the casual links. Drug Information J. 2007;41:229–39.Google Scholar
  11. 11.
    Dimasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151–85.PubMedCrossRefGoogle Scholar
  12. 12.
    Dimasi JA, Hansen RW, Grabowski HG. Cost of innovation in the pharmaceutical industry. J Health Econ. 1991;10:107–42.PubMedCrossRefGoogle Scholar
  13. 13.
    Adams C, Brantner VV. Estimating the costs of new drug development: is it really $802 million. Health Aff 2006;25:420–8.CrossRefGoogle Scholar
  14. 14.
    Matthews M Jr. From inception to ingestion: the cost of creating new drugs, ideas. Bradford: Institute of Pharmaceutical Innovation; 2001. September.Google Scholar
  15. 15.
    Gilbert J, Singh A, Henske P. Rebuilding Big Pharma’s business model. In ViVo 2003;21:10. November, Scholar
  16. 16.
    Grabowski HG, Vernon JA, Dimasi JA. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics. 2002;20(Suppl 3):11–29.PubMedCrossRefGoogle Scholar
  17. 17.
    Dickson M, Gagnon JP. The cost of new drug discovery and development. Discov Med. 2001;4:172–9. June.Google Scholar
  18. 18.
    Said HC. New frontiers in pharma R&D and India’s strengths in new drug discovery. In INDIA CHEM 2002; 2003 (Former Managing Director, Pfizer India).Google Scholar
  19. 19.
    Tollman P, Guy P, Altshuller J, et al. A revolution in R&D: how genomics and genetics will affect drug development costs and times. In: B. C. Group, editor. Pharmaceutical R&D statistical sourcebook. Boston: BCG; 2002–2003.Google Scholar
  20. 20.
    McCormick K. Manufacturing in global pharmaceutical industry. London: Urch; 2003.Google Scholar
  21. 21.
    Benson RS, McCabe JDJ. From good manufacturing practices to good manufacturing performance. Pharmaceutical Engineering 2004;24:26–34. July/August.Google Scholar
  22. 22.
    Raju GK. FDA Science Board Meeting. 2001.Google Scholar
  23. 23.
    Dean D, Bruttin F. Armonk: Metamorphosis of manufacturing; IBM Business Consulting Services; 2005.Google Scholar
  24. 24.
    Hussain A. Final report on PAT and manufacturing science. In FDA Science Board Meeting, 2004.Google Scholar
  25. 25.
    Migliaccio G. FDA will seek consultant help in implementing quality initiative. The GoldSheet, vol. 36, September 2002.Google Scholar
  26. 26.
    Dean D, Bruttin F. The risks and economics of regulatory compliance. PDA J Pharm Sci. 2000;54:253–63. May–Jun.Google Scholar
  27. 27.
    Reinhardt UE. Perspectives on the pharmaceutical industry. Health Aff. 2001;20:136–49. September/October.CrossRefGoogle Scholar
  28. 28.
    Basu PK, Joglekar G, Rai S, Suresh P, Vernon JA. Analysis of manufacturing costs in pharmaceutical companies. J Pharmaceut Innov. 2008;3:30–40. March.CrossRefGoogle Scholar
  29. 29.
    Holcomb M, Rutten P, Fuhr T, Basu PK. Value of implementing quality by design for the pharmaceutical industry. Rockville: FDA; 2008.Google Scholar
  30. 30.
    Codgill RP, Knight TP, Anderson CA, Drennen JK. The financial returns on investments in process analytical technology and lean manufacturing: benchmarks and case study. J Pharmaceut Innov. 2007;2:38.CrossRefGoogle Scholar

Copyright information

© International Society for Pharmaceutical Engineering 2008

Authors and Affiliations

  1. 1.Pharmaceutical Technology and Education CenterPurdue UniversityWest LafayetteUSA

Personalised recommendations